Using complement inhibition to reduce inflammation after subarachnoid hemorrhage
Official title: A Phase II Trial on the Safety and Efficacy of C1 Inhibitor for the Acute Management of Subarachnoid Hemorrhage
Run by Haaglanden Medical Centre · NCT06359782 · Data updated 2026-11-12
This study is testing if a new treatment can help reduce inflammation and improve recovery in patients with bleeding in the brain caused by an aneurysm.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 128 (estimated) |
| Sponsor | Haaglanden Medical Centre Academic / other |
| Locations | 1 site (The Hague, South Holland) |
| Status | Recruiting |
| Started | November 4, 2024 |
| Main results expected | March 2027 |
| Study ends | March 2027 |
| Registry record updated | December 27, 2024 |
| Trial ID | NCT06359782 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with a confirmed diagnosis of aneurysmal subarachnoid hemorrhage.
✕Probably not a fit
Patients with subarachnoid hemorrhage of non-aneurysmal origin or those with a very poor prognosis are unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the safety and efficacy of C1-inhibitor Cinryze in patients diagnosed with aneurysmal subarachnoid hemorrhage (SAH). The study aims to determine if inhibiting the complement system can limit delayed cerebral ischemia and improve clinical outcomes by reducing neuroinflammation. Participants will receive either the C1-inhibitor or a placebo, and their progress will be monitored to assess the treatment's effectiveness. The trial focuses on patients with varying degrees of SAH severity as classified by the WFNS grading system.
Why it matters
Potential benefit: If successful, this treatment could significantly improve recovery outcomes for patients suffering from aneurysmal subarachnoid hemorrhage.
How similar studies have gone: While the approach of complement inhibition is being explored, this specific application in SAH is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmed diagnosis of aneurysmal subarachnoid hemorrhage on CT-scan; * Age ≥ 18 years on admission; * WFNS grade 1-5. Exclusion Criteria: * Subarachnoid hemorrhage deemed most likely of 'peri mesencephalic' origin after consideration of history, clinical examination and radiological findings (including angiographic imaging); (not originated from an aneurysm and patients have by definition a favourable clinical outcome) * Subarachnoid hemorrhage deemed most likely of post-traumatic origin after consideration of history, clinical examination and radiological findings (including angiographic imaging); (does not occur spontaneous) * Participation in another clinical therapeutic study; * Patients with definite infaust prognosis on arrival and/or expected death within 24 hours of admission * Patients with a known hereditary complement deficiency (including hereditary angioedema); * Patients with a history of sensibility to blood products or C1-inhibitor; * Patients with a history of thrombosis (when known at time of inclusion); * Pregnant woman
Where it's running
-
Haaglanden Medical Centre
The Hague, South Holland, Netherlands Recruiting
Study contacts
- Principal investigator: Wouter Moojen, MD PHD — Haaglanden Medisch Centrum
- Study coordinator: Daan de Groot, MD
- Email: daan.de.groot@haaglandenmc.nl
- Phone: 088 979 7900
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding hemorrhage subtypes in perimesencephalic SAH and basilar artery perforator aneurysms
This study tests whether different bleeding patterns in pmSAH, including potential basilar artery perforator aneurysms, relate to patient outcomes using a patient-reported EQ-5D measure.
-
Augmented kidney clearance in neurocritical care
This project will test whether adults in the neuro-ICU with severe brain injury, stroke, seizures, or brain infections have faster kidney clearance (ARC) that can lower antiseizure and antibiotic drug levels.
-
Lidocaine with or without steroid infusion into the middle meningeal artery for headaches after aneurysmal subarachnoid hemorrhage
This study will try an infusion of lidocaine, with or without a steroid, into the middle meningeal artery to see if it reduces severe headaches and opioid use in adults recovering from aneurysmal subarachnoid hemorrhage.
-
Nimodipine blood levels and enantiomer differences in aneurysmal subarachnoid hemorrhage.
This project will test whether different amounts and the two forms of nimodipine get into the blood of adults with aneurysmal subarachnoid hemorrhage and whether that relates to their recovery.
-
Understanding brain and heart injuries after bleeding in the brain
This study looks at how bleeding in the brain affects both the brain and the heart in adults to better understand the connection between these injuries.
-
Remote ischemic conditioning after aneurysm clipping for ruptured brain aneurysms
This test tries brief cycles of limb cuff inflation (remote ischemic conditioning) to see if it is safe and helps recovery in adults after surgical clipping of a ruptured brain aneurysm (aneurysmal subarachnoid hemorrhage).
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.